Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling
release_ulok3z57abhv5plcfog2h46uvq
by
Qing-Bai She,
David Solit,
Andrea Basso,
Mark M Moasser
References
NOTE: currently batch computed and may include additional references sources, or be missing recent changes, compared to entity reference list.| Showing 1 - 16 of 16 references (in 76ms) | ||
|---|---|---|
[b0]via grobid |
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., and Yarden, Y. A hierarchical network of interreceptor interactions determines signal transduction by Neu differ- entiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol., 16: 5276 -5287, 1996.
| |
[b1]via grobid |
Bogdan, S., and Klambt, C. Epidermal growth factor receptor sig- naling. Curr. Biol., 11: R292-R295, 2001.
| |
[b2]via grobid |
Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., and Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 54: 105-115, 1988.
| |
[b3]via grobid |
Matsui, Y., Halter, S. A., Holt, J. T., Hogan, B. L., and Coffey, R. J. Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice. Cell, 61: 1147-1155, 1990.
| |
[b4]via grobid |
Wilks, A. F. Protein tyrosine kinase growth factor receptors and their ligands in development, differentiation, and cancer. Adv. Cancer Res., 60: 43-73, 1993.
| |
[b5]via grobid |
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., and Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC), 244: 707-712, 1989.
| |
[b6]via grobid |
Moasser, M. M., Basso, A., Averbuch, S. D., and Rosen, N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven sig- naling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res., 61: 7184 -7188, 2001.
| |
[b7]via grobid |
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., Bigner, S. H., Giovanella, B. C., Ittmann, M., Tycko, B., Hibshoosh, H., Wigler, M. H., and Parsons, R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (Wash. DC), 275: 1943-1947, 1997.
| |
[b8]via grobid |
Lu, Y., Lin, Y. Z., LaPushin, R., Cuevas, B., Fang, X., Yu, S. X., Davies, M. A., Khan, H., Furui, T., Mao, M., Zinner, R., Hung, M. C., Steck, P., Siminovitch, K., and Mills, G. B. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene, 18: 7034 -7045, 1999.
| |
[b9]via grobid |
Kris, M. G., Ranson, M., Ferry, D., Hammond, L., Averbuch, S., Ochs, J., and Rowinsky, E. Phase I study of oral ZD1839, a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR- TK): evidence of good tolerability and activity. Clin. Cancer Res., 5: 3749s, 1999.
| |
[b10]via fuzzy |
ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial
Malcolm Ranson, Lisa A. Hammond, David Ferry, Mark Kris, Andrew Tullo, Philip I. Murray, Vince Miller, Steve Averbuch (+ more) 2002 Journal of Clinical Oncology doi:10.1200/jco.2002.10.112 pmid:11980995 | |
[b11]via fuzzy |
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo
S L Moulder, F M Yakes, S K Muthuswamy, R Bianco, J F Simpson, C L Arteaga 2001 Cancer Research pmid:11751413 | |
[b12]via fuzzy |
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth
N. Normanno, M. Campiglio, A. De Luca, G. Somenzi, M. Maiello, F. Ciardiello, L. Gianni, D. S. Salomon (+ more) 2002 Annals of Oncology doi:10.1093/annonc/mdf020 pmid:11863114 |
web.archive.org
[PDF]
|
[b13]via fuzzy |
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression
Neil G. Anderson, Tawhid Ahmad, Kai Chan, Richard Dobson, Nigel J. Bundred 2001 International Journal of Cancer doi:10.1002/ijc.1557 pmid:11745477 | |
[b14]via fuzzy |
PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death
L P Weng, W M Smith, P L Dahia, U Ziebold, E Gil, J A Lees, C Eng 1999 Cancer Research pmid:10582703 |
web.archive.org
[PDF]
|
[b15]via grobid |
Li, D. M., and Sun, H. PTEN/MMAC1/TEP1 suppresses the tu- morigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci. USA, 95: 15406 -15411, 1998.
| |